

Glenmark launches affordable drug to treat kidney cancer in India

16 February 2021 | News

The drug is launched at a MRP that is approximately 96 per cent lower than the MRP compared to the innovator brand, priced at Rs 7000 (50 mg), Rs 3600 (25 mg) and Rs 1840 (12.5 mg) per month



Glenmark Pharmaceuticals has launched SUTIB, the generic version of Sunitinib oral capsules to treat kidney cancer in India. The drug is launched at a MRP that is approximately 96 per cent lower than the MRP compared to the innovator brand, priced at Rs 7000 (50 mg), Rs 3600 (25 mg) and Rs 1840 (12.5 mg) per month. Sunitinib is also approved by the US Food and Drug Administration (US FDA).

Sunitinib is an oral multi-kinase inhibitor (MKI), works by blocking several enzymes that promote cell growth. It is useful for the treatment of certain patients with gastrointestinal stromal tumours and advanced renal cell carcinoma. It is also approved for patients with certain type of pancreatic neuroendocrine tumours.

Commenting on the launch, Alok Malik, Group Vice President & Business Head, India Formulations, Glenmark, said, "Oncology is an important focus area for Glenmark. We recognise that advanced kidney cancer is a complex disease and patients in India are faced with limited treatment options. Glenmark is committed to bringing targeted and effective medicines at an affordable cost to physicians and their patients."